Anktiva (interleukin (IL)-15 superagonist nogapendekin alfa inbakicept-pmln) administered with bacillus Calmette-Guérin was approved for adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, according to an April 22 FDA news release.
The drug study found 62% of patients had a complete response; 58% of those with a complete response had a duration of response lasting at least 12 months, and 40% had a duration lasting 24 months or longer.
Previously, the FDA declined approval because of deficiencies the agency observed during its prelicense inspection of third-party manufacturing organizations. In October 2023, ImmunityBio, the company that makes Anktiva, resubmitted its license and it was accepted.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
